KURA ONCOLOGY, INC. Research and Development Expense
KURA ONCOLOGY, INC. (KURA) reported Research and Development Expense of $61.89 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- KURA ONCOLOGY, INC. research and development expense for the quarter ending 2026-06-30 was $61.89M, a 1.42% decline year-over-year.
- KURA ONCOLOGY, INC. research and development expense for the quarter ending 2026-03-31 was $65.26M, a 16.60% increase year-over-year.
- KURA ONCOLOGY, INC. research and development expense for the quarter ending 2025-12-31 was $64.41M, a 23.23% increase year-over-year.
- KURA ONCOLOGY, INC. research and development expense for the quarter ending 2025-09-30 was $67.91M, a 62.83% increase year-over-year.
- KURA ONCOLOGY, INC. research and development expense for fiscal 2025 was $251.07M, a 47.72% increase from fiscal 2024.
- KURA ONCOLOGY, INC. research and development expense for fiscal 2024 was $169.97M, a 47.50% increase from fiscal 2023.
- KURA ONCOLOGY, INC. research and development expense for fiscal 2023 was $115.23M, a 24.16% increase from fiscal 2022.
- KURA ONCOLOGY, INC. research and development expense for fiscal 2022 was $92.81M, a 9.55% increase from fiscal 2021.
| Period end | Research and Development Expense 1 month | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $61.89M 10-Q · filed 2026-08-12 | $127.15M 10-Q · filed 2026-08-12 | $191.56M derived: sum of 3 quarters · filed 2026-08-12 | $259.47M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $65.26M 10-Q · filed 2026-05-12 | $129.67M derived: sum of 2 quarters · filed 2026-05-12 | $197.58M derived: sum of 3 quarters · filed 2026-05-12 | $260.36M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $64.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $132.32M derived: sum of 2 quarters · filed 2026-03-05 | $195.10M derived: sum of 3 quarters · filed 2026-08-12 | $251.07M 10-K · filed 2026-03-05 | |
| 2025-09-30 | $67.91M 10-Q · filed 2025-11-04 | $130.69M derived: sum of 2 quarters · filed 2026-08-12 | $186.67M 10-Q · filed 2025-11-04 | $238.93M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $62.78M 10-Q · filed 2026-08-12 | $118.76M 10-Q · filed 2026-08-12 | $171.03M derived: sum of 3 quarters · filed 2026-08-12 | $212.73M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $55.97M 10-Q · filed 2026-05-12 | $108.24M derived: sum of 2 quarters · filed 2026-05-12 | $149.94M derived: sum of 3 quarters · filed 2026-05-12 | $189.67M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $52.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $93.97M derived: sum of 2 quarters · filed 2026-03-05 | $133.70M derived: sum of 3 quarters · filed 2026-03-05 | $169.97M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $41.70M 10-Q · filed 2025-11-04 | $81.43M derived: sum of 2 quarters · filed 2025-11-04 | $117.70M 10-Q · filed 2025-11-04 | $150.23M derived: sum of 4 quarters · filed 2026-03-05 | |
| 2024-06-30 | $39.73M 10-Q · filed 2025-08-07 | $76.00M 10-Q · filed 2025-08-07 | $108.53M derived: sum of 3 quarters · filed 2026-03-05 | $137.86M derived: sum of 4 quarters · filed 2026-03-05 | |
| 2024-03-31 | $36.27M 10-Q · filed 2025-05-01 | $68.80M derived: sum of 2 quarters · filed 2026-03-05 | $98.13M derived: sum of 3 quarters · filed 2026-03-05 | $126.31M derived: sum of 4 quarters · filed 2026-03-05 | |
| 2023-12-31 | $32.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $61.86M derived: sum of 2 quarters · filed 2026-03-05 | $90.04M derived: sum of 3 quarters · filed 2026-03-05 | $115.23M 10-K · filed 2026-03-05 | |
| 2023-09-30 | $29.33M 10-Q · filed 2024-11-07 | $57.51M derived: sum of 2 quarters · filed 2024-11-07 | $82.70M 10-Q · filed 2024-11-07 | $105.37M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-06-30 | $28.18M 10-Q · filed 2024-08-08 | $53.37M 10-Q · filed 2024-08-08 | $76.04M derived: sum of 3 quarters · filed 2025-02-28 | $101.02M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-03-31 | $25.19M 10-Q · filed 2024-05-02 | $47.86M derived: sum of 2 quarters · filed 2025-02-28 | $72.83M derived: sum of 3 quarters · filed 2025-02-28 | $97.09M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2022-12-31 | $22.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $47.64M derived: sum of 2 quarters · filed 2025-02-28 | $71.90M derived: sum of 3 quarters · filed 2025-02-28 | $92.81M 10-K · filed 2025-02-28 | |
| 2022-09-30 | $24.97M 10-Q · filed 2023-11-02 | $49.23M derived: sum of 2 quarters · filed 2023-11-02 | $70.14M 10-Q · filed 2023-11-02 | $91.10M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $24.26M 10-Q · filed 2023-08-09 | $45.17M 10-Q · filed 2023-08-09 | $66.13M derived: sum of 3 quarters · filed 2024-02-27 | $88.49M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | $20.91M 10-Q · filed 2023-05-10 | $41.87M derived: sum of 2 quarters · filed 2024-02-27 | $64.24M derived: sum of 3 quarters · filed 2024-02-27 | $85.31M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $20.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $43.32M derived: sum of 2 quarters · filed 2024-02-27 | $64.40M derived: sum of 3 quarters · filed 2024-02-27 | $84.72M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $22.37M 10-Q · filed 2022-11-03 | $43.44M derived: sum of 2 quarters · filed 2022-11-03 | $63.77M 10-Q · filed 2022-11-03 | $81.29M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-06-30 | $21.07M 10-Q · filed 2022-08-03 | $41.40M 10-Q · filed 2022-08-03 | $58.92M derived: sum of 3 quarters · filed 2023-02-23 | $75.52M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-03-31 | $20.32M 10-Q · filed 2022-05-04 | $37.85M derived: sum of 2 quarters · filed 2023-02-23 | $54.45M derived: sum of 3 quarters · filed 2023-02-23 | $68.15M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2020-12-31 | $17.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $34.13M derived: sum of 2 quarters · filed 2023-02-23 | $47.82M derived: sum of 3 quarters · filed 2023-02-23 | $60.40M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $16.60M 10-Q · filed 2021-11-04 | $30.30M derived: sum of 2 quarters · filed 2021-11-04 | $42.87M 10-Q · filed 2021-11-04 | $56.34M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-06-30 | $13.70M 10-Q · filed 2021-08-05 | $26.27M 10-Q · filed 2021-08-05 | $39.74M derived: sum of 3 quarters · filed 2022-02-24 | $52.28M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-03-31 | $12.57M 10-Q · filed 2021-05-06 | $26.04M derived: sum of 2 quarters · filed 2022-02-24 | $38.58M derived: sum of 3 quarters · filed 2022-02-24 | $50.02M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2019-12-31 | $13.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $26.00M derived: sum of 2 quarters · filed 2022-02-24 | $37.44M derived: sum of 3 quarters · filed 2022-02-24 | $47.83M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $12.54M 10-Q · filed 2020-11-05 | $23.98M derived: sum of 2 quarters · filed 2020-11-05 | $34.36M 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $11.44M 10-Q · filed 2020-08-06 | $21.82M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $10.38M 10-Q · filed 2020-05-04 | ||||
| 2018-12-31 | $46.79M 10-K · filed 2021-02-24 | ||||
| 2017-12-31 | $26.43M 10-K · filed 2020-02-25 | ||||
| 2015-09-30 | $3.64M 10-Q · filed 2015-11-13 | $6.99M derived: sum of 2 quarters · filed 2015-11-13 | $9.59M 10-Q · filed 2015-11-13 | ||
| 2015-06-30 | $3.35M 10-Q · filed 2015-08-14 | $5.95M 10-Q · filed 2015-08-14 | |||
| 2015-03-31 | $2.60M 10-Q · filed 2015-05-13 | ||||
| 2014-09-30 | $3.00K 10-Q · filed 2015-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |